Patent search ap:("ABBOTT LAB") AND inv:"WITTENBERGER STEVEN J" Page 8

71.

发明专利
未知

公开(公告)号：NO20024678A

公开(公告)日：2002-09-30

申请号：NO20024678

申请日：2002-09-30

Applicant: ABBOTT LAB

Inventor： HILL DAVID R , HSIAO CHI-NUNG , KURUKULA-SURIYA RAVI , WITTENBERGER STEVEN J

IPC: C07D233/74 , C07C239/10 , C07C259/06 , C07D277/34 , C07D317/28 , C07C231/02

CPC classification number: C07D233/74 , C07C259/06 , C07D277/34 , C07D317/28

72.

发明专利
Endothelin antagonists 未知

公开(公告)号：AU748469B2

公开(公告)日：2002-06-06

申请号：AU8592198

申请日：1998-07-27

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A

IPC: C07D491/048 , A61K31/40 , A61K31/41 , A61K31/423 , A61K31/435 , A61K31/4355 , A61K31/495 , A61K31/506 , A61K31/535 , A61K31/55 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/08 , A61P13/12 , A61P21/00 , A61P21/04 , A61P25/06 , A61P35/00 , A61P43/00 , C07D207/16 , C07D207/26 , C07D207/27 , C07D403/04 , C07D405/00 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D491/056

73.

发明专利
未知

公开(公告)号：DK0717741T3

公开(公告)日：2001-08-20

申请号：DK94931741

申请日：1994-08-30

Applicant: ABBOTT LAB

Inventor： LIN NAN-HORNG , HE YUN , ELLIOTT RICHARD L , CHORGHADE MUKUND S , WITTENBERGER STEVEN J , BUNNELLE WILLIAM H , NARAYANAN BIKSHANDAR A , SINGAM PULLA R , ESCH THOMAS K J , BEER DIETER O , WITZIG CHRISTIAN C , HERZIG THOMAS C , RAO ALLA V RAMA

IPC: C07D413/04 , C07D207/09

Abstract: A novel process for preparing enantiomerically-pure 3-methyl-5-(1-(C1-C3-alkyl)-2-pyrrolidinyl)isoxazole in high yield, wherein a protected pyrrolidine or 2-oxo-pyrrolidine starting material is reacted with a suitable organic anion and a resulting beta-keto oxime intermediate is cyclized and dehydrated, as well as intermediates useful in the preparation thereof.

74.

发明专利
PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS 未知

公开(公告)号：SK1452000A3

公开(公告)日：2001-05-10

申请号：SK1452000

申请日：1998-07-27

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A

IPC: C07D491/048 , A61K31/40 , A61K31/41 , A61K31/423 , A61K31/435 , A61K31/4355 , A61K31/495 , A61K31/506 , A61K31/535 , A61K31/55 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/08 , A61P13/12 , A61P21/00 , A61P21/04 , A61P25/06 , A61P35/00 , A61P43/00 , C07D207/16 , C07D207/26 , C07D207/27 , C07D403/04 , C07D405/00 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D491/056

75.

发明专利
Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists 未知

公开(公告)号：NZ330818A

公开(公告)日：2000-05-26

申请号：NZ33081897

申请日：1997-02-12

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN SOO , TASKER ANDREW S , VON GELDERN THOMAS W , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A

IPC: A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin. Endothelin has been shown to constrict arteries and veins, increase mean arterial blood pressure, decrease cardiac output, increase cardiac contractility in vitro, stimulate mitogenesis in vascular smooth muscle including guinea pig trachea, human urinary bladder strips and rat uterus in vitro, induce formation of gastric ulcers, stimulate release of atrial natriuretic factor in vitro and in vivo, increase plasma levels of vasopressin, aldosterone and catecholamines, inhibit release of renin in vitro and stimulate release of gonadotropins in vitro. The compound of formula (I) wherein, Z is -C(R18)(R19)-or -C(O)- wherein R18 and R19 are independently selected from hydrogen and lower alkyl; n is 0 or 1; R is (CH2)m-W wherein m is an integer from 0-6 and W is (a) -C(O)2-G wherein G is H or a carboxy protecting group, (b) -PO3H2, (c) -P(O)(OH)E wherein E is hydrogen, lower alkyl or arylalkyl, (d) -CN, (e) -C(O)NHR17 wherein R17 is lower alkyl, (f) alkylaminocarbonyl, (g) dialkylaminocarbonyl, (h) tetrazolyl, (i) hydroxy, (j) alkoxy, (k) sulfonamido, (l) -C(O)NHS(O)2R16 wherein R16 is loweralkyl, haloalkyl, aryl or dialkylamino, (m) -S(O)2NHC(O)R16, (n)-(u) are represented in the figures provided; R1-R25 are selected from common hydrocarbon groups.